Chugai Pharmaceutical stock
Price history
−12.49% over the period1 year: from ¥8,300.00 (November 18, 2025) to ¥7,263.00 (November 18, 2026), −12.49%.
Show chart data
Closing prices adjusted for splits: the last close of each month.
| Date | Close |
|---|---|
| November 18, 2026 | ¥7,263.00 |
| October 30, 2026 | ¥6,822.00 |
| September 30, 2026 | ¥6,225.00 |
| August 31, 2026 | ¥6,913.00 |
| July 31, 2026 | ¥6,932.00 |
| June 30, 2026 | ¥7,534.00 |
| May 29, 2026 | ¥7,892.00 |
| April 30, 2026 | ¥8,116.00 |
| March 31, 2026 | ¥8,611.00 |
| February 27, 2026 | ¥10,455.00 |
| January 30, 2026 | ¥8,801.00 |
| December 30, 2025 | ¥8,243.00 |
| November 28, 2025 | ¥8,374.00 |
| November 18, 2025 | ¥8,300.00 |
At a glance
The company
Develops and sells pharmaceutical products including oncology, immunosuppressant, and infectious disease treatments globally
Latest results
Quarter to September 30, 2026 · EPS ¥92.95 (estimate ¥74.98)
Next event
Dividend
TickerLandia's take on Chugai Pharmaceutical
- Cheaper than usual relative to earnings: P/E on the latest fiscal year 28 vs a median of 33 over its last 10 fiscal years.
- Pricier than similar companies: trailing 12-month P/E 24 vs 18 (+31%) in a group of 10.
- Strong point: Financial strength (97/100 in its group). Weak point: Dividend (49/100).
Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks
Where the price stands
−32.12% from the 52-week high
Analysts · 15 analysts
Average target¥8,393.33+15.56% vs. price
Buy 10 · Hold 5 · Sell 0 · Buy
TickerLandia Fingerprint: Chugai Pharmaceutical
Compared with similar companies: very high financial strength.
Financials and price compared with 25 companies in the drug manufacturers - general industry, worldwide. Momentum and risk compared with 1,069 Asia-Pacific stocks.
Pricehigh76
How much it costs relative to what it produces.
Metric Value Position in group Price/sales 8.59 94 P/E (trailing 12 months) 24.1 50 Forward P/E 31.3 94 EV/EBITDA 15.9 78 Price/book 5.81 65 Profitabilityhigh75
How much it earns on revenue and capital.
Metric Value Position in group Gross margin 71.5% 30 Operating margin 48.3% 90 Net margin 35.6% 98 ROE 25.3% 69 ROA 18.7% 86 Earnings stabilityhigh64
How steady its margins were over the last five annual reports.
Metric Value Position in group Margin variabilitycounts in reverse: lower means more earnings stability 3.3% 74 Loss-making yearscounts in reverse: lower means more earnings stability 0 of 5 annual reports 54 Growthhigh62
How fast revenue and earnings are growing.
Metric Value Position in group Revenue growth (year over year) +21.50% 86 Earnings growth (year over year) +29.10% 77 Average revenue growth (3 years) −0.05% 22 Financial strengthvery high97
How well it would weather a hard period: debt, liquidity, interest.
Metric Value Position in group Debt/equitycounts in reverse: lower means more financial strength 0.01 98 Current ratio 6.39 98 Net debt/EBITDAcounts in reverse: lower means more financial strength · more cash than debt −0.63 94 Interest coverage 2,892.9 98 Dividendaverage49
How much it returns to shareholders, and for how long.
Metric Value Position in group Payout ratio 69.6% 65 Dividend yield 1.8% 31 Consecutive dividend years 27 years 50 Market momentumaverage50
How the stock has moved compared with the market.
Metric Value Position in group Relative strength (3 months) +21.19% 86 Relative strength (6 months) −5.13% 41 1-year return −12.49% 26 Distance from 200-day average −5.93% 47 Risklow39
How much the price swings.
Metric Value Position in group Volatility (60 days) 32.7% 41 Maximum drawdown (12 months) 42.4% 65 Beta (1 year) 0.12 13
Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 18, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated
Valuation
Chugai Pharmaceutical is cheaper than in the past and pricier than similar companies
On the latest fiscal year's earnings (2025), Chugai Pharmaceutical's P/E today is 27.5, below the median of its last 10 fiscal years (32.8; between 14.8 and 43.4 from 2016 to 2025). Chugai Pharmaceutical's P/E (trailing 12 months): 24.1, +31% against the median of a group of 10 similar companies (18.4).
Compared with 10 similar companies
| Metric | Chugai Pharmaceutical | Position in the group | Band |
|---|---|---|---|
| P/E (trailing 12 months) | 24.1 | Middle | |
| Forward P/E | 31.3 | High | |
| Operating margin | 48.3% | High | |
| ROE | 25.3% | High | |
| Debt/equity | 0.01 | Low |
P/E at fiscal year end; today on the latest fiscal year's earnings. Grey band: the middle half of the group; tick: the median; dot: Chugai Pharmaceutical. All multiples and dividends
TickerLandia analysisHow it is calculated
The financials
The business in numbers
Revenue
¥404.74B
Latest quarter · Q3 2026
Net income
¥143.55B
Latest quarter · Q3 2026
Quarterly net margin
35.5%
Latest quarter · Q3 2026
Numbers and valuation
Full valuation- Market cap
- ¥12.15T
- P/E
- 24.1
- EPS
- ¥306.09
- Volume
- 2.78M
- Daily trading
- €132.62M
- Dividend yield
- 2.93%
How Chugai Pharmaceutical is changing
All resultsRevenue grew 9.8% a year on average over the last 5 years
Operating margin rose from 42.3% to 47.6%
Profits turn into cash: free cash flow equal to 91% of net income
Returns
Chugai Pharmaceutical returns with dividends
¥1,000 invested in Chugai Pharmaceutical 5 years ago, on November 18, 2021, would be worth ¥1,960 today with dividends reinvested: +96.02% in total, +14.41% per year. On price alone it would be ¥1,757 (+75.73%).
| Period | Chugai Pharmaceutical | Nikkei 225 | ¥1,000 becomes |
|---|---|---|---|
| 1 month | +14.67% | −9.15% | ¥1,147 |
| 6 months | −7.89% | −2.91% | ¥921 |
| Year to date | −11.89% | +17.16% | ¥881 |
| 1 year | −10.17% | +21.10% | ¥898 |
| 3 years | +58.85% | +76.65% | ¥1,589 |
| 5 years | +96.02% | +99.26% | ¥1,960 |
| 10 years | +696.37% | +228.25% | ¥7,964 |
Over the last 6 months it has done better than 17% of the stocks in the Healthcare sector.
From 1 year up with dividends reinvested, before taxes; under a year price only. Nikkei 225: price only. Calculate your investment
The chart in detail
Chugai Pharmaceutical: technical analysis
Chugai Pharmaceutical shows no clear trend: the price and its 50- and 200-session averages are not aligned. The price is 30.5% below its all-time closing high (¥10,455.00, February 27, 2026).
- Trend
- No clear trend
- RSI (14 sessions)
- 62
- Between 30 and 70
- vs 200-session average
- −5.93%
Support and resistance
Price areas where Chugai Pharmaceutical has stopped several times in the last year. They describe the chart; they are not forecasts.
- Resistance¥7,995.50+10.09%4 touches, last on July 3, 2026
- Resistance¥7,705.00+6.09%2 touches, last on June 16, 2026
- Resistance¥7,391.50+1.77%2 touches, last on November 5, 2026
- Last price¥7,263.00
- Support¥7,249.33−0.19%3 touches, last on August 13, 2026
- Support¥6,817.50−6.13%2 touches, last on September 24, 2026
Volatility and risk
Over the last year it has moved little with the Nikkei 225.
- Beta (1 year) vs Nikkei 225
- 0.12
- Volatility (60 sessions, annualised)
- 32.7%
- Largest fall in the last year
- −42.43%
In session, November 18, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it
Chugai Pharmaceutical: seasonality
Average monthly price change over 37 years
Over the last 37 years, the strongest month for Chugai Pharmaceutical has been April: +2.33% on average, positive in 19 years out of 37. The weakest has been December: −0.45% on average, positive in 17 years out of 36. November, the current month, has been positive in 18 years out of 36 (+0.24% on average).
Show chart data
| Month | Average | Median | Positive years |
|---|---|---|---|
| January | +1.99% | 0.00% | 17 of 36 |
| February | +1.78% | +1.50% | 21 of 37 |
| March | +1.78% | +1.57% | 22 of 37 |
| April | +2.33% | +0.85% | 19 of 37 |
| May | −0.38% | −1.83% | 16 of 37 |
| June | +1.39% | +1.18% | 20 of 37 |
| July | +0.46% | +0.86% | 20 of 37 |
| August | −0.03% | 0.00% | 18 of 37 |
| September | +0.25% | −0.20% | 17 of 37 |
| October | +1.28% | −1.88% | 15 of 37 |
| November | +0.24% | +0.15% | 18 of 36 |
| December | −0.45% | −0.61% | 17 of 36 |
Price change only, dividends excluded. Past seasonality does not predict future moves.
The company
Chugai Pharmaceutical and its competitors
Chugai Pharmaceutical sells its medicines to customers in Japan and in markets across the world, and it researches, develops, manufactures, imports and exports pharmaceuticals in both. Its product range includes oncology products such as Avastin, Herceptin, Tecentriq, Alecensa, Polivy and Lunsumio, along with Hemlibra, Evrysdi, Mircera, Actemra, Enspryng, PiaSky, Vabysmo and Tamiflu. Among its partnerships, the company is deploying an agentic AI platform with Phylo, Inc. to support biomedical research in drug discovery.
- Headquarters
- Chuo, Japan
- Employees
- 5,104
- Founded
- 1925
- Chief executive
- Osamu Okuda
| Company | Market cap | Operating margin | P/E (trailing 12 months) | 6 months |
|---|---|---|---|---|
| Chugai Pharmaceutical4519 | $76.25B | 48.3% | 24.1 | −7.89% |
| Otsuka Holdings4578 | $41.01B | 18.0% | 17.0 | +9.88% |
| Daiichi Sankyo4568 | $32.83B | 12.6% | 18.8 | +5.65% |
| Astellas Pharma4503 | $30.89B | 23.5% | 12.8 | +18.37% |
| CSPC Pharmaceutical Group1093 | $11.47B | 27.9% | 10.8 | +1.72% |
| BayerBAYN | $61.54B | 16.5% | — | +48.87% |
Same industry or related industries, similar size. Compare Chugai Pharmaceutical with its competitors · Full profile
